| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 使用反义寡核苷酸治疗肺病的方法 | CN96196115.5 | 1996-06-06 | CN1192686A | 1998-09-09 | J·W·尼塞; W·J·梅茨格 |
| 本发明公开了给需要治疗的患者治疗呼吸道疾病的方法。该方法包括向患者局部给予有效治疗呼吸道疾病剂量的反义寡核苷酸,该反义寡核苷酸基本上不含腺苷。药物制剂也被公开。 | ||||||
| 2 | 使用反义寡核苷酸治疗肺病的方法 | CN96196115.5 | 1996-06-06 | CN1134260C | 2004-01-14 | J·W·尼塞; W·J·梅茨格 |
| 本发明公开了给需要治疗的患者治疗呼吸道疾病的方法。该方法包括向患者局部给予有效治疗呼吸道疾病剂量的反义寡核苷酸，该反义寡核苷酸基本上不含腺苷。药物制剂也被公开。 | ||||||
| 3 | 組換えエラスターゼタンパク質ならびにその製造方法および使用 | JP2015094887 | 2015-05-07 | JP6084653B2 | 2017-02-22 | フラナノ,エフ.ニコラス; ブランド,キンバリー; ウォン,マルコ ディー.; ディン,ビー シー. |
| 4 | 組換えエラスターゼタンパク質ならびにその製造方法および使用 | JP2010537075 | 2008-12-04 | JP5829808B2 | 2015-12-09 | フラナノ,エフ.ニコラス; ブランド,キンバリー; ウォン,マルコ ディー.; ディン,ビー シー. |
| 5 | Recombinant elastase proteins as well as processes for the preparation and use thereof | JP2010537075 | 2008-12-04 | JP2011505164A | 2011-02-24 | ディー． ウォン，マルコ; シー． ディン，ビー; フラナノ，エフ．ニコラス; ブランド，キンバリー |
| 本発明は、生物学的に活性な組換えエラスターゼタンパク質の製造、精製、製剤化、および使用のための方法に関する。 前記エラスターゼタンパク質を含む医薬組成物と同様に、治療的に有用なエラスターゼを作製する組換え法が説明される。 新規の組換えエラスターゼタンパク質およびタンパク質調製物もまた開示される。 本発明のエラスターゼタンパク質を含有する医薬組成物を用いて生体導管疾患を治療および予防する方法が説明される。 | ||||||
| 6 | A method of treatment of lung disease using antisense oligonucleotide | JP50165897 | 1996-06-06 | JPH11507218A | 1999-06-29 | ジョナサン ダブリュー． ナイス; ダブリュー．ジェイムズ メッズガー |
| (57)【要約】 治療を必要とする患者において気道疾患を治療する方法について開示する。 該方法は、気道疾患を治療するのに有効な量の、本質的にアデノシンを含まないアンチセンスオリゴヌクレオチドを、局所的に投与することを含む。 また、薬学的処方についても開示する。 | ||||||
| 7 | Recombinant elastase proteins and methods of manufacturing and use thereof | EP13181046.7 | 2008-12-04 | EP2666854A1 | 2013-11-27 | Franano, Nicholas F.; Bland, Kimberly; Wong, Marco D.; Ding, Bee C. |
Methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. |
||||||
| 8 | CRYSTAL STRUCTURE OF ENZYME AND USES THEREOF | EP05819949.8 | 2005-12-13 | EP1828233A2 | 2007-09-05 | REINEMER, Peter; GIELEN-HAERTWIG, Heike; ROSENTRETER, Ulrich; LI, Volkhart; HARRENGA, Axel; SCHOMBURG, Dietmar; NIEFIND, Karsten; HANSEN, Guido, c/o Biota Structural Biology Lab. |
| This invention relates to crystallised human neutrophil elastase and the use of its three-dimensional structure to design modulators for human neutrophil elastase. | ||||||
| 9 | METHOD OF TREATMENT FOR LUNG DISEASES USING ANTISENSE OLIGONUCLEOTIDES | EP96918260 | 1996-06-06 | EP0831848A4 | 2002-03-27 | NYCE JONATHAN W; METZGER W JAMES |
| A method of treating airway disease in a subject in need of such treatment is disclosed. The method comprises topically administering to the subject an antisense oligonucleotide in an amount effective to treat the ariway disease, where the antisense oligonucleotide is essentially free of adenosine. Pharmaceutical formulations are also disclosed. | ||||||
| 10 | METHOD OF TREATMENT FOR LUNG DISEASES USING ANTISENSE OLIGONUCLEOTIDES | EP96918260.0 | 1996-06-06 | EP0831848A1 | 1998-04-01 | NYCE, Jonathan, W.; METZGER, W., James |
| A method of treating airway disease in a subject in need of such treatment is disclosed. The method comprises topically administering to the subject an antisense oligonucleotide in an amount effective to treat the ariway disease, where the antisense oligonucleotide is essentially free of adenosine. Pharmaceutical formulations are also disclosed. | ||||||
| 11 | METHODS OF DETERMINING RISK OF CARDIAC ARRHYTHMIA | US15830886 | 2017-12-04 | US20180156823A1 | 2018-06-07 | Gustav F. Jirikowski; Gottfried H. Kellermann |
| Provided herein are methods of determining a subject's risk of developing a cardiac arrhythmia, methods of treating a subject having or at risk of developing a cardiac arrhythmia, methods of selecting a treatment for a subject having or at risk of developing a cardiac arrhythmia, methods of selecting a subject for administration of a treatment for reducing risk of developing a cardiac arrhythmia, methods of determining the efficacy of a treatment in a subject having or at risk of developing a cardiac arrhythmia, and methods of monitoring a subject having or at increased risk of developing a cardiac arrhythmia based on a level of one or more of glucocorticoid (GC), corticosteroid-binding globulin (CBG), and neutrophil elastase (NE). Also provided are kits that include two or more of an antibody that binds specifically to GC, an antibody that binds specifically to GBC, and an antibody that binds specifically to NE. | ||||||
| 12 | Recombinant Elastase Proteins and Methods of Manufacturing and Use Thereof | US14715660 | 2015-05-19 | US20150329846A1 | 2015-11-19 | F. Nicholas Franano; Kimberly Bland; Marco D. Wong; Bee C. Ding |
| The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | ||||||
| 13 | NOVEL USES OF ELAFIN | US13582738 | 2011-03-02 | US20130281383A1 | 2013-10-24 | Oliver Wiedow; Birge Bargmann; Barbara Kahlke; Lee Shaw; Nils Wichmann |
| The invention relates to novel uses of the polypeptide elafin, and/or homologies, derivatives or fragments thereof having inhibitory activity against leukocyte elastase for the prevention and treatment of medical conditions like SIRS. | ||||||
| 14 | Anti-cancer vaccines | US10927634 | 2004-08-26 | US20060045881A1 | 2006-03-02 | Jeffrey Molldrem |
| The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, neutrophil elastase peptides other than PR1, cyclin E1 peptides, cyclin D peptides, or cyclin E2 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack tumor cells. | ||||||
| 15 | Preparation of elastase | US53824255 | 1955-10-03 | US2886489A | 1959-05-12 | GRANT NORMAN H; ROBBINS KENNETH C |
| 16 | 組換えエラスターゼタンパク質ならびにその製造方法および使用 | JP2017011160 | 2017-01-25 | JP2017104114A | 2017-06-15 | フラナノ,エフ.ニコラス; ブランド,キンバリー; ウォン,マルコ ディー.; ディン,ビー シー. |
| 【課題】生物学的に活性な組換えエラスターゼタンパク質の製造、精製、製剤化、および使用のための方法。 【解決手段】エラスターゼタンパク質を含む医薬組成物と同様に治療的に有用なエラスターゼを作製する組換え法。新規の組換えエラスターゼタンパク質およびタンパク質調製物。エラスターゼタンパク質を含有する医薬組成物を用いて生体導管疾患を治療および予防する方法。 【選択図】なし |
||||||
| 17 | 組換えエラスターゼタンパク質ならびにその製造方法および使用 | JP2015094887 | 2015-05-07 | JP2015172056A | 2015-10-01 | フラナノ,エフ.ニコラス; ブランド,キンバリー; ウォン,マルコ ディー.; ディン,ビー シー. |
| 【課題】エラスターゼ治療において望ましくない作用(例、プロテアーゼ活性化受容体1及び2活性化等)をもたらすトリプシンを含有しない、高純度組換えエラスターゼタンパク質含有医薬組成物の提供。 【解決手段】特定のアミノ酸配列と少なくとも95%の配列同一性を有するアミノ酸配列を含む成熟ヒトI型エラスターゼタンパク質を含む医薬組成物。前記組成物におけるトリプシン含有量は4ng未満であることが好ましい。前記組成物は、動脈又は静脈等の生体導管疾患用いることができる。 【選択図】なし |
||||||
| 18 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF | US15880029 | 2018-01-25 | US20180155703A1 | 2018-06-07 | F. Nicholas FRANANO; Kimberly Bland; Marco D. Wong; Bee C. Ding |
| The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | ||||||
| 19 | Crystal Structure of Enzyme and Uses Thereof | US11793367 | 2005-12-13 | US20100003709A1 | 2010-01-07 | Peter Reinemer; Heike Gielen-Haertwig; Ulrich Rosentreter; Volkhart Li; Axel Harrenga; Dietmar Schomburg; Karsten Niefind; Guido Hansen |
| This invention relates to crystallised human neutrophil elastase and the use of its three-dimensional structure to design modulators for human neutrophil elastase. | ||||||
| 20 | Low adenosine agent, composition, kit and method for treatment of airway disease | US474497 | 1995-06-07 | US5994315A | 1999-11-30 | Jonathan W. Nyce; W. James Metzger |
| An oligonucleotide which is antisense to a mRNA encoding a polypeptide involved in airway disease(s) contains up to three adenosines per every 21 nucleotide a method of treating airway disease in a subject in need of such treatment comprises topically administering to the subject an antisense oligonucleotide in an amount effective to treat the airway disease, where the antisense oligonucleotide is essentially free of adenosine. Pharmaceutical formulations are also disclosed. | ||||||
QQ群二维码
意见反馈
意见反馈